Pheburane (sodium phenylbutyrate) vs Olpruva (sodium phenylbutyrate)
Pheburane (sodium phenylbutyrate) vs Olpruva (sodium phenylbutyrate)
Pheburane (sodium phenylbutyrate) and Olpruva (sodium phenylbutyrate) are both formulations of sodium phenylbutyrate, a medication used in the treatment of urea cycle disorders, which are genetic conditions that affect the body's ability to remove ammonia from the bloodstream. Pheburane is a specially formulated microgranule version designed to mask the bitter taste and improve patient compliance, especially in children, whereas Olpruva is a newer, taste-masked, orally disintegrating tablet form that also aims to enhance palatability and adherence. When deciding between the two, factors such as the patient's preference for dosage form, taste sensitivity, ease of administration, and insurance coverage should be considered, along with consultation with a healthcare provider.
Difference between Pheburane and Olpruva
| Metric | Pheburane (sodium phenylbutyrate) | Olpruva (sodium phenylbutyrate) |
|---|---|---|
| Generic name | Sodium phenylbutyrate | Sodium phenylbutyrate |
| Indications | Urea cycle disorders | Urea cycle disorders |
| Mechanism of action | Converts to phenylacetate which conjugates with glutamine to form phenylacetylglutamine, which is then excreted by the kidneys | Converts to phenylacetate which conjugates with glutamine to form phenylacetylglutamine, which is then excreted by the kidneys |
| Brand names | Pheburane | Olpruva |
| Administrative route | Oral | Oral |
| Side effects | Body odor, gastrointestinal disturbances, headache, fatigue | Body odor, gastrointestinal disturbances, headache, fatigue |
| Contraindications | Hypersensitivity to sodium phenylbutyrate or any component of the product | Hypersensitivity to sodium phenylbutyrate or any component of the product |
| Drug class | Urea cycle disorder agent | Urea cycle disorder agent |
| Manufacturer | Lucane Pharma | Horizon Therapeutics |
Efficacy
Efficacy of Sodium Phenylbutyrate in ALS
Sodium phenylbutyrate, marketed under brand names such as Pheburane and Olpruva, is a medication that has been explored for its potential efficacy in the treatment of Amyotrophic Lateral Sclerosis (ALS), a progressive neurodegenerative disease. While sodium phenylbutyrate is traditionally used for the treatment of urea cycle disorders, its off-label use in ALS has been the subject of clinical research due to its potential neuroprotective properties and ability to mitigate stress on the endoplasmic reticulum in neuronal cells.
Studies investigating the efficacy of sodium phenylbutyrate in ALS patients have shown mixed results. Some clinical trials have suggested that the drug may have a positive impact on the disease's progression and patients' quality of life. For instance, sodium phenylbutyrate is hypothesized to promote neuronal cell survival and reduce the accumulation of misfolded proteins, which are implicated in the pathogenesis of ALS. However, these findings are preliminary and further research is needed to conclusively determine the drug's efficacy in this context.
It is important to note that the use of sodium phenylbutyrate for ALS is considered off-label, meaning it is not approved by regulatory agencies specifically for this condition. Physicians may prescribe it on a case-by-case basis, taking into account the individual patient's clinical situation and the existing evidence for its potential benefits and risks. The decision to use sodium phenylbutyrate for ALS should be made in consultation with a healthcare professional who is experienced in the management of neurodegenerative diseases.
As of the current knowledge cutoff date, there is no definitive cure for ALS, and treatment primarily focuses on managing symptoms and improving patients' quality of life. In this context, sodium phenylbutyrate may offer some therapeutic benefits, but its role in the treatment of ALS remains an area of active investigation. Patients and caregivers considering the use of sodium phenylbutyrate for ALS should engage in a thorough discussion with their healthcare team to understand the potential risks and benefits of this off-label treatment option.
Regulatory Agency Approvals
Pheburane
-
European Medical Agency (EMA), European Union
-
Food and Drug Administration (FDA), USA
Olpruva
-
Food and Drug Administration (FDA), USA
Access Pheburane or Olpruva today
If Pheburane or Olpruva are not approved or available in your country (e.g. due to supply issues), you can access them via Everyone.org.
How it works
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Make an enquiry
Choose the medicine you want to buy, answer a couple of questions, and upload your prescription to speed things up. We’ll get back to you within 24 hours.
Breeze through the paperwork
We'll guide you through the required documents for importing unapproved medicine, ensuring you have all the necessary information.
Get a personalized quote
We’ll prepare a quote for you, including medicine costs and any shipping, administrative, or import fees that may apply.
Receive your medicine
Accept the quote and we’ll handle the rest - sourcing and safely delivering your medicine.
Some text on this page has been automatically generated. Speak to your physician before you start a new treatment or medication.
Let's talk
If you have any questions, call us or send us a message through WhatsApp or email:
Contact us